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Abstract
BRF1 is a rate-limiting factor for RNA Polymerase III-mediated transcription and is elevated in numerous cancers. Here, we
report that elevated levels of BRF1 associate with poor prognosis in human prostate cancer. In vitro studies in human
prostate cancer cell lines demonstrated that transient overexpression of BRF1 increased cell proliferation whereas the
transient downregulation of BRF1 reduced proliferation and mediated cell cycle arrest. Consistent with our clinical
observations, BRF1 overexpression in a Pten-deﬁcient mouse (PtenΔ/Δ BRF1Tg) prostate cancer model accelerated prostate
carcinogenesis and shortened survival. In PtenΔ/Δ BRF1Tg tumours, immune and inﬂammatory processes were altered, with
reduced tumoral inﬁltration of neutrophils and CD4 positive T cells, which can be explained by decreased levels of
complement factor D (CFD) and C7 components of the complement cascade, an innate immune pathway that inﬂuences the
adaptive immune response. We tested if the secretome was involved in BRF1-driven tumorigenesis. Unbiased proteomic
analysis on BRF1-overexpresing PC3 cells conﬁrmed reduced levels of CFD in the secretome, implicating the complement
system in prostate carcinogenesis. We further identify that expression of C7 signiﬁcantly correlates with expression of CD4
and has the potential to alter clinical outcome in human prostate cancer, where low levels of C7 associate with poorer
prognosis.
Introduction
The BRF1 transcription factor functions together with
TATA-binding protein and B double-prime 1 in a complex
called TFIIIB. BRF1 is required to recruit RNA polymerase
III (Pol III) to target genes and is rate-limiting for Pol III-
mediated transcription [1]. Increased protein synthesis plays
a key role in oncogenesis and Pol III products, including
transfer RNAs (tRNAs) and other short non-coding RNAs,
such as the ribosomal component 5S RNA, are essential for
protein synthesis. Major components of the ribosome
(ribosomal proteins e.g. RPS-19, -21, -24 and ribosomal
RNA) are upregulated in prostate cancer (PCa) [2, 3]. BRF1
expression is elevated and associated with poor prognosis in
hepatocellular, breast and gastric cancers [4–6] but its role
in PCa remains unclear.
PCa is the third most common cause of cancer-associated
death in men worldwide and progression is unpredictable
[7]. Patients with similar tumour grade and histology can
quickly progress to incurable, advanced metastatic disease
These authors contributed equally: Carolyn J. Loveridge, Sarah Slater,
Kirsteen J. Campbell
* Hing Y. Leung
h.leung@beatson.gla.ac.uk
1 Institute of Cancer Sciences, College of Medical, Veterinary and
Life Sciences, University of Glasgow, Bearsden, Glasgow G61
1QH, UK
2 CRUK Beatson Institute, Bearsden, Glasgow G61 1BD, UK
3 Northern Institute for Cancer Research, The Medical School,
Newcastle University, Framlington Place, Newcastle upon Tyne
NE2 4HH, UK
4 Institute of Infection, Immunity and Inﬂammation, College of
Medical, Veterinary and Life Sciences, University of Glasgow,
Glasgow G12 8TA, UK
5 Present address: Department of Basic Sciences and Oral Biology,
Faculty of Dentistry, Universiti Sains Islam Malaysia,
Kuala Lumpur, Malaysia
Supplementary information The online version of this article (https://
doi.org/10.1038/s41388-019-1106-x) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
or alternatively they can survive for decades with local,
indolent, disease [8]. Evasion of surveillance and recogni-
tion by the innate and adaptive immune system are
implicated in PCa progression [9] and it has been proposed
that oncogenic drivers can contribute to immunoresistance
in PCa [10]. There is an unmet need to better understand
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these biological processes in PCa which tends to resist
available immune checkpoint inhibitors.
The complement pathway links innate and adaptive
immunity to coordinate appropriate immune responses [11].
Complement activation occurs via the classical, lectin or
alternative pathways [12], culminating in the formation of
the membrane attack complex (MAC) (composed of C5b-
C9) which punctures cell membranes to cause cytolysis.
The concentration of C7 at sites of complement activation is
a limiting factor for MAC formation [13]. Complement
activation recruits neutrophils, monocytes and macrophages
to sites of inﬂammation [14], promotes opsonisation of B-
cell responses [12] and enhances T-cell responses (activa-
tion, differentiation, polarisation and apoptosis) [11, 12].
Here, we show that elevated BRF1 associates with poor
prognosis in PCa and accelerates prostate tumorigenesis in a
new genetically engineered mouse model. For the ﬁrst time,
we demonstrate that elevated BRF1 expression in the
prostatic epithelium can impact upon the tumour micro-
environment in vivo.
Results
BRF1 is elevated in prostate cancer and confers a
poor prognosis
BRF1 immunoreactivity was studied in 516 PCa cases and
134 benign prostatic hyperplasia (BPH) controls. Nuclear
BRF1 immunoreactivity (Fig. 1a) was signiﬁcantly upre-
gulated in PCa (p= 0.0032) (Fig. S1a, Table S1) and in
clinically signiﬁcant disease (Gleason sum score= 7 and >
7: p= 0.0039 and 0.0091, respectively) (Fig. S1b, Table
S2) when compared with BPH. Elevated BRF1 expression
correlated with shorter disease-speciﬁc survival (5.39 vs.
7.81 years; p= 0.012) (Fig. 1b, Table S3). Utilising the
Memorial Sloan-Kettering Cancer Center (MSKCC) (2010)
[15] and The Cancer Genome Atlas (TCGA) (provisional)
prostate adenocarcinoma datasets in cBioPortal [16, 17],
elevated BRF1 expression also associated with poor out-
come (Figs. 1c, d and S1c, d; Tables S4 and S5).
BRF1 drives in vitro cellular proliferation and cell
cycle progression
BRF1 expression was assessed in human PCa cell lines
(Fig. S1e). Ectopic overexpression of BRF1, using HA-
BRF1 or eGFP-BRF1 plasmids, mediated a modest but
signiﬁcant increase in cell proliferation in PC3, PC3M and
DU145 cells by WST1 assay (Figs. 1e, S2a and S3a; Table
S6). Conversely, downregulation of BRF1 expression in
PCa cells (with at least two out of three independent siR-
NAs) reduced proliferation (Figs. 1f, S2b and S3b; Table
S7), with FACS analysis revealing reduced
G1 subpopulation and increased G2 phase (Fig. 1g, h).
Collectively, manipulation of BRF1 expression alters pro-
liferation in vitro.
Increased BRF1 accelerates prostate tumourigenesis
in vivo
An in vivo model with prostate epithelium-speciﬁc over-
expression of BRF1 was generated by inter-crossing BRF1
mice [18] with the Pbsn (PB)-Cre4 strain [19] to generate
PB-Cre4:BRF1 (herein referred to as BRF1Tg) mice (see
Supplementary methods; Fig. 2a). Male BRF1Tg mice were
aged to over 1 year, and no malignancy or alteration in
prostate architecture was observed (n= 12 WT; n= 12
BRF1Tg) (Fig. 2b). We then crossed BRF1Tg with Ptenﬂ/ﬂ
[20] mice to generate prostate epithelium-speciﬁc double
mutant PB-Cre4:Ptenﬂ/ﬂ BRF1 (herein referred to as PtenΔ/Δ
Fig. 1 BRF1 is a prognostic marker in prostate cancer and mediates
effects on cellular proliferation and the cell cycle in vitro. a Example
images of PCa cores stained for BRF1 with varying Histoscores:
negative (score 0), low (score 125), intermediate (score 175) or high
(score 300). Higher magniﬁcation images show ﬁner detail of staining
from the same cores. Scale bars are shown (100 µm for lower mag-
niﬁcation images; 10 µm for higher magniﬁcation images). b
Kaplan–Meier plot for disease-speciﬁc survival of PCa patients stra-
tiﬁed according to low (below median histoscore; n= 128) versus high
(above median histoscore; n= 137) expression of BRF1 within PCa
cohort. c Kaplan–Meier plot for progression-free survival of patients in
MSKCC (2010) dataset segregated for low and high BRF1 expression
as indicated in oncoprint in Fig. S1c. d Kaplan–Meier plot for
progression-free survival of patients in TCGA (provisional) dataset
segregated for low and high BRF1 expression as indicated in oncoprint
in Fig. S1d. Log-rank (Mantel–Cox) Test was performed to compare
survival curves; *p < 0.05. e Forest plot summarising WST1 cell
proliferation assay results from PC3, PC3M and DU145 (all n= 3)
cells which were transiently transfected with HA-BRF1, GFP-BRF1
and their respective HA- and GFP-empty vector controls for 48 h. f
Forest plot summarising WST1 cell proliferation assay results from
PC3 (n= 4), PC3M, DU145, LNCaP and LNCaP AI (all n= 3) cells
which were transiently transfected with three independent siRNAs for
BRF1 and control non-targeting (NT) siRNA for 48 h. In presented
Forest plots in e and f, each box represents the sample mean [relative
to empty vector (e) or control NT siRNA (f)]; error bars represent 95%
conﬁdence intervals; the centre of the diamond in summary line
represents the collective sample mean; the width of the diamond
represents the 95% conﬁdence interval for the collective sample mean.
PC3 (g) and PC3M (h) cells were transiently transfected with two
independent siRNAs for BRF1 and two different control NT siRNAs
for 72 h then subjected to bromodeoxyuridine (BrdU)- and propidium
iodide (PI)-labelling followed by ﬂow cytometry analysis to determine
cell cycle positions. Data presented are from n= 3 (PC3 cells: NT
siRNA 2; BRF1 siRNA’s 2 and 3), n= 4 (PC3 cells: NT siRNA 3;
PC3M cells: NT siRNA 3) or n= 5 (PC3M cells: NT siRNA 2; BRF1
siRNA’s 2 and 3) experiments. Individual data points are shown in the
presented graphs; long horizontal lines indicate the Mean; error bars
represent SEM; 2way ANOVA was used to calculate p values; *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 from NT siRNA 2 or 3
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BRF1Tg) mice. Survival of PB-Cre4:Ptenﬂ/ﬂ (herein referred to
as PtenΔ/Δ) control mice was consistent with our previous
report [21]. PtenΔ/Δ BRF1Tg mice had signiﬁcantly shorter
disease-speciﬁc survival compared with PtenΔ/Δ siblings
(median 256 vs 316 days, respectively; p < 0.0001) (Fig. 2c,
Table S8), with comparable endpoint tumour weights (Fig.
2d, Table S9) despite being harvested earlier. Interestingly,
whilst high BRF1 protein levels were observed in all PtenΔ/Δ
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BRF1Tg tumours, some tumours from PtenΔ/Δ mice also had
elevated BRF1 expression (Fig. 2e). Quantitative real-time
PCR (qPCR) was performed using primers speciﬁc for
human BRF1 conﬁrmed its overexpression in PtenΔ/Δ
BRF1Tg prostate tumours (p= 0.0459) (Fig. 2f). PtenΔ/Δ and
PtenΔ/Δ BRF1Tg tumours were found to be histologically
similar (Fig. 2g). High BRF1 expression was found in the
prostate epithelium of BRF1Tg (Fig. 2b) and PtenΔ/Δ BRF1Tg
(Fig. 2h) mice as expected. Although levels of Ki67 and
cleaved caspase-3, markers for proliferation and apoptosis,
respectively, were similar (Fig. S4a, b), we observed a
signiﬁcant reduction in the expression of the cell cycle
inhibitor p21 in PtenΔ/Δ BRF1Tg tumours (p= 0.0151) (Fig.
2h, i), consistent with the cell cycle data in Fig. 1g, h.
Together these data suggest that increased expression of
BRF1 alone does not drive PCa but can co-operate with
Pten loss.
PtenΔ/Δ BRF1Tg prostate tumours harbour alterations
in immune system processes
RNA-Sequencing (RNA-Seq) identiﬁed 522 signiﬁcantly
altered genes (fold change > 1.5; p.adj < 0.05) between
PtenΔ/Δ and PtenΔ/Δ BRF1Tg endpoint tumours, with 174
coding genes involved in immune processes (see heatmap in
Fig. 3a; Table S10)—these are predominantly down-
regulated in PtenΔ/Δ BRF1Tg tumours. Gene enrichment
analysis further identiﬁed immune system processes,
inﬂammatory response and leukocyte chemotaxis amongst
the most overrepresented biological processes (Fig. 3b and
Table S11).
Untargeted proteomics analysis on the PtenΔ/Δ and PtenΔ/Δ
BRF1Tg tumours revealed that the abundance of 300 proteins
was signiﬁcantly (fold change > 1.5; p.adj < 0.05) altered,
with 52 of these being related to immune processes (Fig. 3c,
Table S12). Pathway enrichment analysis subsequently
revealed that 7 of the top 10 most overrepresented biological
processes related to immune responses (Fig. 3d and Table
S13).
Finally, analysis of the top 10 overrepresented pathways
(Table S14) in both RNA-Seq and proteomics again pointed
towards altered immune status as a key difference between
PtenΔ/Δ and PtenΔ/Δ BRF1Tg prostate tumours, highlighting
aspects of both the innate immune response and the adap-
tive immune response.
Inﬁltration of neutrophils, CD3 and CD4 positive T
lymphocytes is signiﬁcantly reduced in PtenΔ/Δ
BRF1Tg (compared with PtenΔ/Δ) tumours
Analysis of innate immune cells showed no signiﬁcant
difference in the level of macrophages but neutrophils were
signiﬁcantly reduced (p= 0.0421) in the stroma (deﬁned in
Fig. S5a) of PtenΔ/Δ BRF1Tg versus PtenΔ/Δ prostate tumours
(Figs. 3e, f and S5c). Consistent with our previous report
[21] and clinical PCa [22], stromal tertiary lymphoid
aggregates were present in murine tumours (Fig. S5b),
neither the total area of these structures nor markers of B-
cell response were unaltered (Figs. S6 and S7a, b). PtenΔ/Δ
BRF1Tg tumours contained signiﬁcantly fewer stromal CD3
and CD4 T cells (p= 0.0438, 0.0394, respectively) but
stromal CD8 or FOXP3 (a marker for regulatory T cells)
T cells were not altered (Figs. 3g–i, S5d, c).
Collectively, we identiﬁed reduced inﬁltration of neu-
trophils and CD4 positive T lymphocytes in PtenΔ/Δ BRF1Tg
prostate tumours, in keeping with reduced levels of
immune/inﬂammatory response genes (Fig. 3a) and
expression of Cd4 (RNA-Seq data: log2FoldChange=
−1.8203; p.adj= 0.0067; Table S8) in prostate tumours
from PtenΔ/Δ BRF1Tg mice.
Fig. 2 Double mutant PtenΔ/Δ BRF1Tg mice have reduced survival
compared with PtenΔ/Δ mice. a Illustration of strategy for targeting
overexpression of human BRF1 gene. The mouse Hprt genomic locus,
the Hprt targeting vector (including the human BRF1 transgene) and
the restored Hprt locus (with transgene inserted on 5’ side) are shown.
b Representative micrographs of H+ E and BRF1 IHC staining in
anterior prostate tissue from WT and BRF1Tg mice (n= 5 for each
genotype). Scale bars are shown (100 µm for all images).
c Kaplan–Meier plot representing disease-speciﬁc survival of BRF1Tg
(n= 12), PtenΔ/Δ (n= 12) and PtenΔ/Δ BRF1Tg (n= 14) mice. Log-rank
(Mantel–Cox) Test was performed to compare PtenΔ/Δ and PtenΔ/Δ
BRF1Tg survival curves; ****p < 0.0001. d Representative images of
isolated prostates from PtenΔ/Δ and PtenΔ/Δ BRF1Tg mice that had
reached clinical endpoint and a wild type (WT) mouse taken at an
equivalent age (top panel). Isolated prostates from PtenΔ/Δ (n= 12) and
PtenΔ/Δ BRF1Tg (n= 14) mice were weighed prior to removal of cystic
ﬂuid (termed Wet Weight), then were re-weighed to assess the solid
tumour mass (termed Dry Weight) (bottom panel). e Whole-cell
lysates prepared from prostate tumour tissue obtained from PtenΔ/Δ (n
= 4) and PtenΔ/Δ BRF1Tg (n= 4) mice were subjected to SDS-PAGE,
followed by western blotting using an anti-BRF1 antibody.
HSP70 served as a loading control. f qPCR analysis of RNA isolated
from prostate tumour tissue obtained from PtenΔ/Δ (n= 3) and PtenΔ/Δ
BRF1Tg (n= 3) mice speciﬁcally for the human BRF1 transgene.
Casc3 was used as a reference gene for normalisation. g Representa-
tive micrographs of H+ E staining in anterior prostate tissue from
PtenΔ/Δ and PtenΔ/Δ BRF1Tg mice (n= 5 for each genotype). Red box
in lower magniﬁcation images in upper panel highlights region shown
in higher magniﬁcation images in lower panel. Scale bars are shown
(1 mm for upper panel images; 100 µm for bottom panel images).
h Representative micrographs of BRF1, Ki67, Cleaved Caspase-3 and
p21 IHC staining in anterior prostate tumour tissue from PtenΔ/Δ and
PtenΔ/Δ BRF1Tg mice (n= 5 for each genotype). Yellow arrows
highlight p21 staining. Scale bars are shown (100 µm for all images).
i Scoring of p21 IHC staining. p21 IHC staining was analysed in 25
manually annotated areas of prostate tumour epithelium per slide from
PtenΔ/Δ (n= 5) and PtenΔ/Δ BRF1Tg (n= 5) mice using HALO soft-
ware (see methods). d, f, i Individual data points are shown in the
presented graphs; long horizontal line indicates the Mean; error bars
represent SEM; Welch’s t test (unpaired, 2 tailed) was used to calculate
p value; *p < 0.05
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PtenΔ/Δ BRF1Tg tumours have reduced complement
pathway activation
We generated an in vitro model system by engineering PC3
clones to stably express eGFP-tagged BRF1 (BRF1 CL4, 5,
6), or eGFP empty vector (Ctrl CL1, 2) as controls. Parental
PC3 and CL1 and CL2 cells exhibited similar protein
synthesis (Fig. S8a) and so CL2 was thereafter used as a
representative control. Overexpression of BRF1 (Fig. 4a)
resulted in signiﬁcantly increased protein synthesis [p.adj=
0.0132 (CL4); 0.0024 (CL5); 0.0047 (CL6)] (Fig. 4b),
demonstrating BRF1 expression promoted Pol III function
as expected.
Stable isotope labelling by amino acids in cell culture
followed by mass spectrometry (Fig. S8b) on culture media
from BRF1 overexpressing PC3 cells revealed 33 common
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proteins which had > 1.2 fold change in abundance in the
same direction in CL4, CL5 and 6 compared with Ctrl CL2
(Fig. 4c; Table S15). Reduced levels of complement factor
D (CFD) in the secretome of BRF1 overexpressing cells
was validated (Fig. 4d) and this was particularly interesting
because the complement pathway, including C7, an ‘end-
point’ component of the MAC, was highlighted from RNA-
Seq and proteomic data (Tables S10 and S14). Reduced C7
mRNA (p= 0.0244) (Fig. 4e) and CFD and C7 protein
expression (Fig. 4f) was validated in murine prostate
tumours. Taken together, these data indicate that comple-
ment pathway activation is reduced in PtenΔ/Δ BRF1Tg
tumours.
Low C7 levels are clinically relevant in human
prostate cancer
In clinical PCa cBioPortal data, alterations in BRF1 and C7
signiﬁcantly co-occurred when interrogating all (p= 0.002)
and metastatic (p < 0.0001) tumour cases in MSKCC (2010)
dataset (Fig. 4g, h). Segregating cases revealed that patients
with low C7 expression (Fig. S8c, d) have a poorer prog-
nosis in both datasets (Fig. 4i, j; Tables S16 and 17), in
keeping with mouse model data. Furthermore, an inverse
correlation between BRF1 and C7 mRNA expression and a
positive correlation between CFD and C7 mRNA expres-
sion was found in both MSKCC (2010) and TCGA (pro-
visional) datasets (BRF1 vs C7: Pearson correlation
coefﬁcient, r=−0.307; p= 0.0001 and r=−0.173; p=
0.0001, respectively; C7 vs CFD: Pearson correlation
coefﬁcient, r= 0.490; p < 0.0001 and r= 0.495; p < 0.0001,
respectively) (Figs. 4k, S8e–g).
Complement activation can enhance the differentiation
and activation of T lymphocytes [12]. In both MSKCC
(2010) and TCGA (provisional) datasets, a positive rela-
tionship between C7 and the status of either CD3E
[MSKCC: Pearson correlation coefﬁcient, r= 0.324; p <
0.0001; TCGA: Pearson correlation coefﬁcient, r= 0.139;
p= 0.0019] or CD4 [MSKCC: Pearson correlation coefﬁ-
cient, r= 0.356; p < 0.0001; TCGA: Pearson correlation
coefﬁcient, r= 0.205; p < 0.0001] (Fig. S8h–k) was
observed, consistent with mouse model data.
In summary (Fig. 4l), BRF1 expression is elevated in
clinical PCa and its overexpression promotes prostate car-
cinogenesis in an established GEM model in vivo. Aberrant
complement pathway activation, as indicated by altered
secretion of CFD in vitro and reduced levels of CFD and C7
in vivo, is mechanistically consistent with the observed
altered immune inﬁltrates, including neutrophils and CD4
positive T cells, within the tumour microenvironment upon
elevation of BRF1.
Discussion
For the ﬁrst time, we show that BRF1 expression drives
prostate carcinogenesis in vitro and in vivo. Recent work
has highlighted that the repertoire of tRNAs expressed in
oncogenic contexts speciﬁcally supports the production of
proteins for a proliferative program [23]. Increases in spe-
ciﬁc tRNAs such as the initiator methionine tRNAiMet are
sufﬁcient to promote migration and invasive behaviour in
melanoma cells [24] and for ﬁbroblasts to secrete collagen,
which in turn enhanced tumour growth and angiogenesis
[25], suggesting that BRF1 may play a major role in
orchestrating altered programs of tRNA and thus protein
synthesis. In support of this, we found that increased
expression of BRF1 upregulated global protein synthesis
in vitro and mediated a switch in cellular programme,
manifesting with an altered secretome.
To our knowledge, this is the ﬁrst study to report effects
of BRF1 on the immune response in an in vivo model. A
previous study identiﬁed a direct effect of Pol III activity in
enhancing macrophage phagocytic function in vitro [26].
Our study did not target Pol III activity directly in immune
cells, but instead we show that elevated expression of BRF1
is associated with altered immune cell inﬁltration in an
in vivo model of prostate carcinogenesis.
Fig. 3 Transcriptomics and proteomics reveal that immune system
processes are signiﬁcantly altered in PtenΔ/Δ BRF1Tg mice and inﬁl-
tration of neutrophils and CD4 positive T lymphocytes is signiﬁcantly
reduced in PtenΔ/Δ BRF1Tg compared with PtenΔ/Δ mice. a Heatmap of
RNA-Seq data. Presented are the 174 genes that are implicated in
immune processes which have signiﬁcantly altered expression (>1.5-
fold change; p.adj < 0.05) between PtenΔ/Δ and PtenΔ/Δ BRF1Tg pros-
tate tumours. Because of a technical problem, the library preparation
step for one PtenΔ/Δ sample failed resulting in n= 2 for PtenΔ/Δ and n
= 3 for PtenΔ/Δ BRF1Tg. In the heatmap, blue represents down-
regulation of gene expression (Row Z-Score < 0); red represents up-
regulation of gene expression (Row Z-Score > 0). b Bar chart illus-
trating results of gene enrichment analysis from GeneGO MetaCore of
RNA-Seq data – the top 10 signiﬁcantly altered GO processes are
shown; highlighted in red are those which relate to the immune
response. c Volcano plot of proteomic data from comparison of PtenΔ/Δ
(n= 4) and PtenΔ/Δ BRF1Tg (n= 3) prostate tumour samples. High-
lighted in red are proteins whose abundance was found to be sig-
niﬁcantly (fold change > 1.5; p.adj < 0.05) altered between PtenΔ/Δ and
PtenΔ/Δ BRF1Tg samples; amongst these signiﬁcantly altered proteins,
highlighted in green are those that related to the immune process GO
term (Table S10). d Bar chart illustrating results of gene enrichment
analysis from GeneGO MetaCore of proteomic data – the top 10 sig-
niﬁcantly altered GO processes are shown; highlighted in red are those
which relate to the immune response. Analysis of IHC staining for F4/
80 (e), NIMP (f), CD3 (g), CD4 (h) and CD8 (i). Total observable
prostate stromal tissue per slide was manually annotated on each
sample from PtenΔ/Δ (n= 5) and PtenΔ/Δ BRF1Tg (n= 5) mice for each
marker then staining within these annotated areas was analysed using
HALO software (see supplementary information). e–i Individual data
points are shown in the presented graphs; long horizontal line indicates
the Mean; error bars represent SEM; Welch’s t test (unpaired, 2 tailed)
was used to calculate p value; *p < 0.05
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It is recognised that immune inﬁltration can have a sig-
niﬁcant inﬂuence upon clinical outcome in cancer patients
[22]. Our previous study found that improved survival upon
genetic loss of Erk5 in PtenΔ/Δ PCa model was related to
increased levels of the T cell recruiting cytokines Ccl5 and
Cxcl10 and enhanced T cell inﬁltration (predominantly
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CD4+) within the tumours [21]. Here, we report an asso-
ciation between reduced levels of CD4+ T lymphocytes,
and also neutrophils, with poorer survival in PtenΔ/Δ BRF1Tg
compared with PtenΔ/Δ mice.
The complement pathway has been reported to have both
pro- and anti-tumourigenic effects [11]. We observe that a
low complement C7 environment is associated with poorer
survival in our transgenic mouse model and human PCa.
Furthermore, in both murine and human PCa, tumoral
CD4+ T cell level positively correlated with complement
C7 level. These data signiﬁcantly contribute to our under-
standing of how the complement system may contribute to
tumourigenesis.
In conclusion, our data highlight that elevated BRF1
expression promotes prostate carcinogenesis. We implicate
a non-cell autonomous role for high Brf1 expression in the
prostatic epithelium as impacting on the tumour micro-
environment with altered immune inﬁltrates. Given the
rapid pace of development of cancer therapies targeting the
immune system, further research in this area is warranted.
Materials and methods
Experimental methodology
Detail for the following experimental procedures is pro-
vided in Supplementary Materials and Methods: IHC; ISH;
image analysis of IHC and ISH staining; histoscore; use and
analysis of clinical datasets; culture of human PCa cell
lines; transient transfection of plasmids and siRNA’s; gen-
eration of PC3 eGFP empty vector and eGFP-PRF1 stable
clones; western blotting; WST-1 cell proliferation assay;
cell cycle analysis from BrdU labelling; generation of
conditional human BRF1 expressing mice; mouse strains
and breeding; quantitative real-time PCR (Table S18); iso-
lation and quantiﬁcation of RNA (Table S19); RNA-
sequencing and bioinformatic analysis; SILAC labelling
and preparation of secretome samples; proteomics; com-
parison of RNA-Seq and proteomics data and 35S-
Methionine incorporation assay.
Human tissue microarray
Tissue microarrays (TMAs) consisting of cores of formalin-
ﬁxed, parafﬁn-embedded (FFPE) tissue from a cohort of
134 individuals with BPH and 516 patients with primary
PCa were analysed for expression of BRF1 by immuno-
histochemistry. See Table S20 for demographic data at
diagnosis: Age—median= 69.5 years (interquartile range
(IQR) 63–75.5); Gleason sum score—median= 7 (IQR
6–8) (60.8% cases ≥ 7); Serum PSA levels—median=
15.55 ng/ml (IQR 7.025–44).
Statistics
Statistical analyses, including: Mann–Whitney, Log-rank
(Mantel–Cox), Pearson correlation coefﬁcient, Welch’s t
test (unpaired, 2 tailed) and Kaplan–Meier survival analysis,
were performed using GraphPad Prism v7.02 or IBM SPSS
Statistics 25 software. Bonferroni correction for multiple
testing was performed as indicated. For all graphs, mean ±
standard deviation (SD) or standard error of mean (SEM)
(error bars) are presented and these are deﬁned for each
ﬁgure. In Forest plots, in both the upregulated and down-
regulated cases, the data were pooled (across all cell-lines),
log-transformed, and a one-sample t-test was performed.
Fig. 4 Complement pathway activation is (i) reduced when BRF1 is
overexpressed in vitro, (ii) reduced in prostate tumours from PtenΔ/Δ
BRF1Tg mice and (iii) inversely correlates with BRF1 expression in
human PCa. a Western blotting of whole-cell lysates prepared from
PC3 Ctrl CL2 and BRF1 CL4, 5 and 6 cells using anti-BRF1 antibody
and HSC70 as a loading control. Blot shown is representative of three
independent experiments. b Comparison of incorporation of 35S-
methionine label, which was measured by scintillation counting,
between PC3 stable clones (n= 3; 2-3 wells per clone were used per
each individual experiment). Data from BRF1 CL4, 5 and 6 cells were
normalised to the mean of PC3 Ctrl CL2 cells. Individual data points
are shown in the presented graph; long horizontal line indicates the
Mean; error bars represent SEM; Welch’s t test (unpaired, two tailed)
with Bonferroni correction for multiple testing was used to calculate p.
adj values; *p.adj < 0.05; **p.adj < 0.01. c Venn diagram outlining
numbers of proteins that had >1.2-fold change in abundance in the
same direction in PC3 BRF1 overexpressing clones CL4, 5 and 6
compared with Ctrl CL2. d Western blotting of puriﬁed secreted
proteins prepared from PC3 Ctrl. CL2 and PC3 BRF1 overexpressing
CL4, 5 and 6 using an anti-CFD antibody. PonceauS staining was used
as a loading control. e qPCR analysis of isolated RNA prepared from
prostate tumour tissue obtained from PtenΔ/Δ (n= 5) and PtenΔ/Δ
BRF1Tg (n= 5) mice for C7. Casc3 was used as a reference gene for
normalisation. Individual data points are shown in the presented graph;
long horizontal line indicates the Mean; error bars represent SEM;
Welch’s t test (unpaired, 2 tailed) was used to calculate p value; *p <
0.05. f Western blotting of whole-cell lysates prepared from prostate
tumour tissue obtained from PtenΔ/Δ (n= 5) and PtenΔ/Δ BRF1Tg (n=
5) mice using anti-C7 and anti-CFD antibodies. HSC70 served as a
loading control. Oncoprint from cBioPortal illustrating mRNA
expression proﬁle in BRF1 and C7 in all tumours (216 cases) (g) and
metastatic tumours (37 cases) (h) in MSKCC (2010) prostate adeno-
carcinoma dataset. Kaplan–Meier plots for progression-free survival in
MSKCC (2010) (i) and TCGA (provisional) (j) prostate adenocarci-
noma datasets of patients segregated for low and high C7 expression as
indicated in the Oncoprints presented in Fig. S8c, d, respectively. Log-
rank (Mantel–Cox) Test was performed to compare survival curves;
*p < 0.05; ***p < 0.001. k Scatter plot showing the correlation of C7
and BRF1 mRNA expression in MSKCC (2010) prostate adeno-
carcinoma dataset (n= 150; all tumours with mRNA expression data).
Pearson correlation coefﬁcient and p value for the comparison is stated
in the main text. l Schematic summary of key observations as
described in the main text
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